PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma

Plain-language summary

Published 2019 in Nat Commun, this work by Fons NR and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

• Mechanistic study in Nat Commun (2019) on NAD+/sirtuin/longevity biology
• Adds to the foundational literature underlying NMN supplementation rationale
• First author: Fons NR

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to science decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.